Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined methods that facilitate the successful recruitment and retention of patients - an essential element to delivering clinical studies on time.

The article focuses on the growing emphasis on improved patient engagement in trial development.  A key element in the success of clinical trials lies in the availability and subsequent experience of people volunteering to participate. It is therefore crucial that Richmond Pharmacology and trial sponsors understand patients’ lives and the factors that drive a patient’s decision to take part in a study. Examples are shared in the article about effective ways of doing this.

Richmond Pharmacology understands the importance of having a good relationship with patient volunteers. This can be achieved by removing potential barriers to trial participation, as well as ensuring that the volunteer is treated as an individual, rather than given a one-size-fits-all experience. Keith also highlights other criteria that sponsors should look for in a Contract Research Organisation (CRO) regarding patient retention – for example a guarantee that a trial will take place in a single centre research facility and that interaction with patients is never outsourced to a third party.

To read the full article, click here

Latest news

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Unlocking the potential of data sharing

January 4, 2023
Dilshat Djumonov explores how GDPR is central to protecting private information while presenting unique challenges to the pharmaceutical clinical trials industry.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event